Volition expands clinical development of Nu.Q to Asia Pacific

12 July 2018 (Last Updated July 12th, 2018 10:39)

Belgium-based cancer diagnostics firm Volition has expanded the clinical trial programme of its Nu.Q platform, being developed to detect colorectal cancer, to the Asia Pacific Region.

Belgium-based cancer diagnostics firm Volition has expanded the clinical trial programme of its Nu.Q platform, being developed to detect colorectal cancer, to the Asia Pacific Region.

The expansion includes the execution of agreements with the National Taiwan University (NTU) to carry out two multi-country, multi-centre studies in multi-ethnic Asian participants.

Nu.Q is designed as a series of simple, cost-effective and accurate blood tests which analyse samples for the presence of early nucleosome markers of cancer. This is intended to facilitate early diagnosis and treatment.

“The expansion includes the execution of agreements with the National Taiwan University (NTU) to carry out two multi-country, multi-centre studies in multi-ethnic Asian participants.”

NTU Internal Medicine department clinical professor Han-Mo Chiu said: “The early detection of colorectal cancer could benefit the survival rate of patients significantly.

“There is a clear need for a product which not only has high accuracy but is also easy to use and affordable, such as a routine blood test.”

The two trials being performed at the university, will involve 5,000 asymptomatic and 2,000 symptomatic colorectal cancer patients, respectively. Their main objective is to validate the capability of Nu.Q to detect and diagnose colorectal cancer, for marketing purposes.

Recently, Volition also executed an agreement with the National University of Singapore to conduct a 719-subject trial.

Singapore Volition CEO Jasmine Kway said: “At a cost of approximately $2.55m payable over three years, these large-scale studies are in line with Volition’s other great value studies and demonstrate our commitment to conducting large yet cost-effective trials worldwide to drive the acceptance of our products.

“These studies are pivotal for Volition’s strategy for the Asia Pacific Region where incidence of colorectal cancer is increasing.”

The Nu.Q platform is already being evaluated in about 45,000 European subject cohorts and more than 13,500 cohorts in the US.